<DOC>
	<DOCNO>NCT01008410</DOCNO>
	<brief_summary>The purpose study establish efficacy profile rectally administer budesonide foam administer 2mg/25mL BID 2 week follow 2mg/25mL QD 4 week , compare equivalent volume rectally administer placebo foam dose schedule , subject present diagnosis active , mild moderate , ulcerative proctitis ( UP ) ulcerative proctosigmoiditis ( UPS ) . During study , eligible subject allow maintain previously establish oral 5-ASA treatment dose 4.8g/day .</brief_summary>
	<brief_title>Efficacy Safety Budesonide Foam Patients With Active Mild Moderate Ulcerative Proctitis Proctosigmoiditis</brief_title>
	<detailed_description>This Phase 3 , randomize , double-blind , placebo-controlled , multi-center study ass efficacy safety budesonide foam subject active mild moderate proctitis proctosigmoiditis . Approximately 430 subject enrol study receive either placebo foam budesonide foam twice day 2 week follow day 4 week . Participation study last approximately 11 week , depend timing study visit . During study , eligible subject allow maintain previously establish oral 5-ASA treatment dose 4.8g/day . Periodic safety monitoring , include physical examination , vitals , laboratory testing , record AEs concomitant medication , perform study</detailed_description>
	<mesh_term>Ulcer</mesh_term>
	<mesh_term>Proctitis</mesh_term>
	<mesh_term>Proctocolitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<mesh_term>Hormones , Hormone Substitutes , Hormone Antagonists</mesh_term>
	<mesh_term>Peripheral Nervous System Agents</mesh_term>
	<criteria>Voluntarily sign write informed consent . Male nonpregnant nonlactating female â‰¥18 year age . Confirmed diagnosis ( endoscopy procedure ) active , mild moderate ulcerative proctitis proctosigmoiditis extend 40cm anal verge . Must possess baseline MMDAI score 5 10 . Visible blood stool . History current diagnosis Crohn 's disease indeterminate colitis . Prior gastrointestinal surgery except appendectomy hernia . Concomitant active gastrointestinal disease distortion intestinal anatomy . History diverticulitis , collagenous colitis , celiac disease , recurrent pancreatic know gallbladder disease . Uncontrolled , previously diagnose type 1 2 diabetes mellitus . Uncontrolled abnormal thyroid function . Unstable significant cardiovascular , endocrine , neurologic pulmonary disease . Hemoglobin level &lt; 7.5 g/dL . History sclerosing cholangitis , cirrhosis , hepatic impairment . Renal disease manifest &gt; 2.0mg/dL serum creatinine . History avascular hip necrosis , active tuberculosis , ocular herpes simplex ocular varicella zoster , malignant disease , HIV hepatitis B C. Adrenal insufficiency . Active systemic cutaneous infection toxic megacolon , fistula , perforation abscess . History uncontrolled psychiatric disorder seizure disorder . History asthma require ongoing use inhaled steroid . Recent history drug alcohol abuse . Positive stool test bacterial pathogen , C diff O &amp; P . Vaccination within 28 day prior Randomization . Allergies budesonide item use preparation . Participation another clinical trial past 30 day . Pregnant risk pregnancy . Taking prohibited medication . Some medication treat UP/UPS prohibit participation study , include laxative antidiarrhea medication ; however , oral 5ASA agent dose 4.8g/day daily fiber supplement allow . Other medication ( e.g. , antibiotic , antiseizure anticoagulant medicine ) also prohibit .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Proctitis</keyword>
	<keyword>Proctosigmoiditis</keyword>
	<keyword>Ulcerative</keyword>
	<keyword>Salix</keyword>
	<keyword>Budesonide foam</keyword>
	<keyword>Budesonide</keyword>
	<keyword>Rectal</keyword>
	<keyword>Gastrointestinal</keyword>
	<keyword>Colitis</keyword>
	<keyword>UC</keyword>
	<keyword>UP</keyword>
	<keyword>UPS</keyword>
	<keyword>Additional relevant MeSH term :</keyword>
	<keyword>Proctocolitis</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Colitis , Ulcerative</keyword>
	<keyword>Gastroenteritis</keyword>
	<keyword>Gastrointestinal Diseases</keyword>
	<keyword>Digestive System Diseases</keyword>
	<keyword>Rectal Diseases</keyword>
	<keyword>Intestinal Diseases</keyword>
	<keyword>Colonic Diseases</keyword>
	<keyword>Sigmoid Diseases</keyword>
	<keyword>Pathologic Processes</keyword>
	<keyword>Inflammatory Bowel Diseases</keyword>
	<keyword>Bronchodilator Agents</keyword>
	<keyword>Autonomic Agents</keyword>
	<keyword>Peripheral Nervous System Agents</keyword>
	<keyword>Physiological Effects Drugs</keyword>
	<keyword>Pharmacologic Actions</keyword>
	<keyword>Anti-Asthmatic Agents</keyword>
	<keyword>Respiratory System Agents</keyword>
	<keyword>Therapeutic Uses</keyword>
	<keyword>Glucocorticoids</keyword>
	<keyword>Hormones</keyword>
	<keyword>Hormones , Hormone Substitutes , Hormone Antagonists</keyword>
	<keyword>Anti-Inflammatory Agents</keyword>
</DOC>